Skip to content

#Trial results

17 NovTue
  1. Psychedelic Alpha78

    Helus Pharma reports positive topline results from first phase 3 trial of HLP003 in major depressive disorder

    Helus Pharma, formerly Cybin, announced a positive topline readout from its first phase 3 study of HLP003, a deuterated psilocin analog, for the adjunctive treatment of major depressive disorder (MDD). The trial is part of the company's PARADIGM phase 3 program, which tests HLP003 as an adjunctive treatment in adults who have had an inadequate response. The announcement gives no effect size, adverse event data or participant numbers.

14 SepMon
22 AugSat
12 AugWed
22 JunMon
  1. STAT: psychedelics83

    Definium says LSD therapy DT120 helped major depression in first Phase 3 trial

    Definium Therapeutics said on Monday that its LSD therapy DT120 significantly helped patients with major depression in its first Phase 3 trial. Six weeks after a single dose.

    Why it matters: The topline gives the first Phase 3 readout for an LSD-based depression treatment, so the size of the placebo gap and the waning at 12 weeks are the numbers that will shape the next regulatory step.